2,501
Views
5
CrossRef citations to date
0
Altmetric
Genomics

Genetic testing for amyotrophic lateral sclerosis in Canada – an assessment of current practices

, , , , , , , , , , , , , , , , , ORCID Icon, , , & show all
Pages 305-312 | Received 28 Jul 2021, Accepted 12 Sep 2021, Published online: 27 Sep 2021

References

  • Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55.
  • Byrne S, Bede P, Elamin M, Kenna K, Lynch C, McLaughlin R, et al. Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:157–9.
  • Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7:603–15.
  • Vajda A, McLaughlin RL, Heverin M, Thorpe O, Abrahams S, Al-Chalabi A, et al. Genetic testing in ALS: a survey of current practices. Neurology. 2017;88:991–9.
  • Hardiman O, van den Berg LH. The beginning of genomic therapies for ALS. N Engl J Med. 2020;383:180–1.
  • Perrone B, Conforti FL. Common mutations of interest in the diagnosis of amyotrophic lateral sclerosis: how common are common mutations in ALS genes? Expert Rev Mol Diagn. 2020;20:703–14.
  • van Es MA, Dahlberg C, Birve A, Veldink JH, van den Berg LH, Andersen PM. Large-scale SOD1 mutation screening provides evidence for genetic heterogeneity in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:562–6.
  • Brown CA, Lally C, Kupelian V, Flanders WD. Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants. Neuroepidemiology. 2021;55:1–12.
  • Shepheard SR, Parker MD, Cooper-Knock J, Verber NS, Tuddenham L, Heath P, et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92(5):510–518.
  • Grassano M, Calvo A, Moglia C, Brunetti M, Barberis M, Sbaiz L, American Genomic Center, et al. Mutational analysis of known ALS genes in an Italian population-based cohort. Neurology. 2021;96:e600–e9.
  • Hodgkinson VL, Lounsberry J, Mirian A, Genge A, Benstead T, Briemberg H, et al. Provincial differences in the diagnosis and care of amyotrophic lateral sclerosis. Can J Neurol Sci. 2018;45:652–9.
  • Klepek H, Nagaraja H, Goutman SA, Quick A, Kolb SJ, Roggenbuck J. Lack of consensus in ALS genetic testing practices and divergent views between ALS clinicians and patients. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:216–21.
  • Arthur KC, Doyle C, Chio A, Traynor BJ. Use of genetic testing in amyotrophic lateral sclerosis by neurologists. JAMA Neurol. 2017;74:125–6.
  • Martin D, Miller AP, Quesnel-Vallée A, Caron NR, Vissandjée B, Marchildon GP. Canada's universal health-care system: achieving its potential. Lancet. 2018;391:1718–35.
  • Srinivasan E, Rajasekaran R. A systematic and comprehensive review on disease-causing genes in amyotrophic lateral sclerosis. J Mol Neurosci. 2020;70:1742–1770.
  • Wang MD, Gomes J, Cashman NR, Little J, Krewski D. Intermediate CAG repeat expansion in the ATXN2 gene is a unique genetic risk factor for ALS-a systematic review and meta-analysis of observational studies. PLoS One. 2014;9:e105534.
  • Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88:540–9.
  • , Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis A, P. M, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)-revised report of an EFNS task force. Eur J Neurol. 2012;19:360–75.
  • Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, et al. Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler. 2007;8:195–213.
  • Benatar M, Stanislaw C, Reyes E, Hussain S, Cooley A, Fernandez MC, et al. Presymptomatic ALS genetic counseling and testing: experience and recommendations. Neurology. 2016;86:2295–302.
  • Crook A, Williams K, Adams L, Blair I, Rowe DB. Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling considerations. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:475–85.
  • Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93:1617–28.
  • van Eijk RPA, Westeneng HJ, Nikolakopoulos S, Verhagen IE, van Es MA, Eijkemans MJC, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92:e451–e460.
  • Shoesmith C, Abrahao A, Benstead T, Chum M, Dupre N, Izenberg A, et al. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. CMAJ. 2020;192:E1453–E68.
  • Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Quality Standards Subcommittee of the American Academy of Neurology, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1218–26.